Tezepelumab (Tezspire®) : new biological treatment of severe asthma
Here we present pharmacological and clinical properties of a new biological targeting TSLP (Thymic Stromal LymphoPoietin). Tezspire® is the name of this targeted treatment which contains 210 mg tezepelumab administered subcutaneously once a month. As compared to placebo, tezepelumab reduced exacerbations whatever the baseline blood eosinophil counts, exhaled nitric oxide (FeNO) level and atopic status. The response was higher in patients exhibiting the highest levels of blood eosinophils and FeNO. Tezepelumab also improved pre- bronchodilatation forced expiratory volume in one second, symptomatic control of asthma and quality of life. Tezepelumab proved a broad anti-inflammatory effect by blocking IL-4, IL-13 and IL-5 pathways, inducing a significant reduction in serum total IgE levels, FeNO, blood and sub-mucosal eosinophils, without affecting neutrophil level. Tezepelumab also reduced bronchial hyperresponsiveness and mucus plugs.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Revue medicale de Liege - 79(2024), 1 vom: 15. Jan., Seite 60-64 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère |
|---|
| Beteiligte Personen: |
Schleich, Florence [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 16.01.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM367145286 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367145286 | ||
| 003 | DE-627 | ||
| 005 | 20240116232112.0 | ||
| 007 | tu | ||
| 008 | 240115s2024 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367145286 | ||
| 035 | |a (NLM)38223972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Schleich, Florence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tezepelumab (Tezspire®) |b new biological treatment of severe asthma |
| 246 | 3 | 3 | |a Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Here we present pharmacological and clinical properties of a new biological targeting TSLP (Thymic Stromal LymphoPoietin). Tezspire® is the name of this targeted treatment which contains 210 mg tezepelumab administered subcutaneously once a month. As compared to placebo, tezepelumab reduced exacerbations whatever the baseline blood eosinophil counts, exhaled nitric oxide (FeNO) level and atopic status. The response was higher in patients exhibiting the highest levels of blood eosinophils and FeNO. Tezepelumab also improved pre- bronchodilatation forced expiratory volume in one second, symptomatic control of asthma and quality of life. Tezepelumab proved a broad anti-inflammatory effect by blocking IL-4, IL-13 and IL-5 pathways, inducing a significant reduction in serum total IgE levels, FeNO, blood and sub-mucosal eosinophils, without affecting neutrophil level. Tezepelumab also reduced bronchial hyperresponsiveness and mucus plugs | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Monoclonal antibody | |
| 650 | 4 | |a Severe asthma | |
| 650 | 4 | |a Tezepelumab | |
| 650 | 4 | |a Thymic stromal lymphopoietin | |
| 650 | 7 | |a tezepelumab |2 NLM | |
| 650 | 7 | |a RJ1IW3B4QX |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Sabbe, Mare |e verfasserin |4 aut | |
| 700 | 1 | |a Moermans, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Renaud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale de Liege |d 1947 |g 79(2024), 1 vom: 15. Jan., Seite 60-64 |w (DE-627)NLM000044490 |x 0370-629X |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:1 |g day:15 |g month:01 |g pages:60-64 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 1 |b 15 |c 01 |h 60-64 | ||